ArticleClinical endocrinology2026
Mass Spectrometric Measurements of 11-Deoxycortisol, Androstenedione and Dehydroepiandrosterone Are Superior to Cortisol to Assess Selectivity of Non-Stimulated Adrenal Vein Sampling.
Article in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Apparent Bilateral Aldosterone Suppression During Adrenal Vein Sampling: An Artefact of the Liaison Chemiluminescence Immunoassay and Other Causes Revealed by Comparisons With Another Commercial Immunoassay and Mass Spectrometry.Clinical endocrinology · 2026Observational
- Mass Spectrometric Measurements of 11-Deoxycortisol, Androstenedione and Dehydroepiandrosterone Are Superior to Cortisol to Assess Selectivity of Non-Stimulated Adrenal Vein Sampling.Clinical endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveSuccessful adrenal venous sampling (AVS) is traditionally assessed using the ratio of cortisol in adrenal to peripheral venous plasma to calculate the selectivity index. With mass spectrometry other steroids can be simultaneously measured that may improve numbers of apparent successful sampling procedures.
designCross-sectional multicenter study. PATIENTS: The study involved 229 patients who underwent unstimulated AVS for subtyping primary aldosteronism. MEASUREMENTS: Adrenal and peripheral venous plasma cortisol, 11-deoxycortisol, androstenedione and dehydroepiandrosterone were measured by mass spectrometry to assess AVS selectivity. Ratios of aldosterone, measured by mass spectrometry, to each of the four steroids in right versus left adrenal venous plasma were used to assess lateralisation.
resultsSelectivity indices for 11-deoxycortisol, androstenedione and dehydroepiandrosterone were respectively 5.7-(CI 5.1-6.2), 5.1-(CI 4.8-5.4) and 5.9-(CI 5.5-6.4) fold higher (p < 0.0001) than for cortisol. At selectivity index cut-offs of ≥ 3 and ≥ 2, rates of bilateral successful AVS were respectively 91% and 93% for 11-deoxycortisol, 90% and 91% for androstenedione and 89% and 91% for dehydroepiandrosterone, all higher (p < 0.0001) than the 69% and 85% respective success rates for cortisol. With 11-deoxycortisol, rates of apparent unsuccessful AVS procedures were reduced by 54%-72% compared to use of cortisol. There were no clear advantages of any single steroid over the others to assess lateralized aldosterone secretion.
conclusions11-Deoxycortisol, androstenedione and dehydroepiandrosterone are more suitable biomarkers than cortisol to assess AVS selectivity and allow rescue of many procedures otherwise deemed unsuccessful. Measurements of cortisol to assess AVS selectivity are best replaced by mass spectrometric measurements of other steroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.